Suppliers / Shenzhen Techdow Pharmaceutical

Shenzhen Techdow Pharmaceutical

China 2 duplicate records merged Updated 9 July 2026

Shenzhen Techdow Pharmaceutical is an API manufacturer based in China. It holds 2 active US drug master files. Its filings concentrate with Health Canada, ARCSA (EC) and INVIMA (CO). Its GMP standing is certified by EMA, MFDS (Korea) and ANVISA (Brazil). Its most recent recorded inspection, by US FDA, closed on 17 September 2019 as VAI.

2
active US DMFs
0
valid CEPs
2
registered plants 1 with an FDA FEI number
34
filings across 6 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 17 September 2019 VAI US FDA
  • 23 January 2015 NAI US FDA
  • 15 March 2012 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
SHENZHEN, China Not on file
China, China 3005599762

What they file, and where

Molecule Regulators Docs
Enoxaparin US FDA 2

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
Health Canada 13 None
ARCSA (EC) 12 None
INVIMA (CO) 3 None
EFDA (ET) 3 None
MINSA (CR) 2 None
UZPHARM (UZ) 1 None
EMA None 4
MFDS (Korea) None 2
ANVISA (Brazil) None 1

Comparing suppliers?

Choose your molecules and target markets. Shenzhen Techdow Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 17 September 2019.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates